// App-Quantinova.ai

2730 : Efficacy and Safety of Romosozumab vs Placebo Among Patients with Mild-to-Moderate Chronic Kidney Disease

Researchers

Presenter

  • Arkadi Chines

Principal Investigators

  • Ben-Hur Albergaria

  • Evelien Gielen

  • Bente Langdahl

  • Akimitsu Miyauchi

  • Mark Vanderkelen

  • Cassandra Milmont

  • Judy Maddox

  • Jonathan Adachi

Medical Centers

  • Colorado Center for Bone Research at Panorama Orthopedics and Spine Center, Golden, CO

  • Amgen Inc, Thousand Oaks, CA

  • Federal Univ. of Espirito Santo, Vitoria, Brazil

  • Gerontology and Geriatrics, Department of Chronic Diseases, Metabolism and Aging, KU Leuven & Center for Metabolic Bone Diseases, UZ Leuven, Leuven, Belgium

  • Aarhus University Hospital, Aarhus, Denmark

  • Miyauchi Medical Center, Osaka, Japan

  • UCB Pharma, Brussels, Belgium

  • McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada

Locations

  • United States

  • Brazil

  • Belgium

  • Denmark

  • Japan

  • Canada

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Nephrology

Disease

  • Chronic kidney disease

  • Renal insufficiency

  • Renal disease

Biomarkers

  • Bone Mineral Density

Drug/Treatment

  • Romosozumab

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved